Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Eosinophil-Lactobacillus quadruple therapy for first treatment of Helicobacter pylori-positive chronic gastritis
ChiCTR2400082227Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Mar 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound lactobacillus acidophilus in Helicobacter pylori infection and chronic gastritis (3 arms), sponsored by Peking University First Hospital. Primary endpoint: Helicobacter pylori eradication rate. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
compound lactobacillus acidophilus
03
Conditions
Helicobacter pylori infectionchronic gastritis
Beyond the preview
Go deeper on ChiCTR2400082227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082227.